SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (Nasdaq: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to restore some functional vision to blind patients, today announced that Health Canada has approved the Argus® II Retinal Prosthesis System to treat individuals with severe to profound outer retinal degeneration.
The Argus II, implanted in more than 100 individuals worldwide, is the only retinal prosthesis approved by Health Canada and the U.S. Food and Drug Administration (FDA), and the first approved retinal prosthesis in the world. The system induces visual perception in blind individuals by providing electrical pulses to stimulate the retina’s remaining cells, resulting in a perception of light patterns in the brain. The Argus II has the potential to offer life changing visual capabilities to those with little or no remaining functional vision. The Argus II implant can positively impact a blind person’s ability to conduct routine daily activities, such as recognizing shapes or large objects, locating people, identifying the location of doorways, and following lines or edges. Ultimately, this is meant to allow Argus II users to live their daily lives with more confidence.
Help employers find you! Check out all the jobs and post your resume.
